Vanguard Personalized Indexing Management LLC purchased a new position in Medpace Holdings, Inc. (NASDAQ:MEDP – Get Rating) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 950 shares of the company’s stock, valued at approximately $202,000.
A number of other institutional investors have also recently made changes to their positions in MEDP. UBS Group AG lifted its position in Medpace by 185.1% during the fourth quarter. UBS Group AG now owns 23,896 shares of the company’s stock worth $5,076,000 after buying an additional 15,513 shares in the last quarter. Gladstone Institutional Advisory LLC purchased a new stake in Medpace in the fourth quarter valued at $302,000. Los Angeles Capital Management LLC raised its position in Medpace by 34.2% in the fourth quarter. Los Angeles Capital Management LLC now owns 24,039 shares of the company’s stock valued at $5,106,000 after purchasing an additional 6,125 shares during the period. AXA S.A. raised its position in Medpace by 27.1% in the third quarter. AXA S.A. now owns 44,600 shares of the company’s stock valued at $7,010,000 after purchasing an additional 9,500 shares during the period. Finally, Gabelli Funds LLC purchased a new stake in Medpace in the third quarter valued at $204,000. 82.49% of the stock is owned by institutional investors and hedge funds.
Insider Transactions at Medpace
In other news, CEO August J. Troendle sold 31,648 shares of the company’s stock in a transaction dated Tuesday, April 25th. The stock was sold at an average price of $221.83, for a total transaction of $7,020,475.84. Following the completion of the transaction, the chief executive officer now directly owns 6,451,371 shares of the company’s stock, valued at approximately $1,431,107,628.93. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 25.70% of the company’s stock.
Medpace Price Performance
MEDP opened at $206.97 on Thursday. Medpace Holdings, Inc. has a 12 month low of $130.79 and a 12 month high of $241.48. The stock has a market capitalization of $6.31 billion, a price-to-earnings ratio of 26.20 and a beta of 1.42. The business has a fifty day moving average price of $198.09 and a 200 day moving average price of $206.51.
Medpace (NASDAQ:MEDP – Get Rating) last released its earnings results on Monday, April 24th. The company reported $2.27 EPS for the quarter, topping the consensus estimate of $1.76 by $0.51. Medpace had a return on equity of 75.20% and a net margin of 16.44%. The firm had revenue of $434.07 million during the quarter, compared to analysts’ expectations of $402.83 million. During the same period in the previous year, the firm posted $1.69 EPS. Medpace’s revenue for the quarter was up 31.2% on a year-over-year basis. On average, research analysts anticipate that Medpace Holdings, Inc. will post 8.11 earnings per share for the current year.
Analyst Ratings Changes
A number of research firms have commented on MEDP. Guggenheim upgraded Medpace from a “neutral” rating to a “buy” rating and set a $252.00 target price on the stock in a research report on Monday, May 8th. Robert W. Baird lifted their target price on Medpace from $226.00 to $233.00 and gave the company a “neutral” rating in a research report on Wednesday, February 15th. 22nd Century Group reiterated an “upgrade” rating on shares of Medpace in a report on Monday, May 8th. Finally, StockNews.com upgraded Medpace from a “hold” rating to a “buy” rating in a report on Friday, May 12th. Two research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $241.00.
Medpace Company Profile
(Get Rating)
Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.
Read More
Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Get Rating).
Receive News & Ratings for Medpace Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Medpace and related companies with MarketBeat.com’s FREE daily email newsletter.